Abstract

Background

Microwave ablation (MWA) is a safe and effective locoregional ablation modality, but it is not clear whether the curative effect of MWA as to hepatocellular carcinoma (HCC) is comparable to that of surgical resection (SR). We aimed to compare the outcomes of MWA and SR for patients with HCC ranging from 3 to 5 cm.

Methods

197 patients treated for HCC between 3 and 5 cm by MWA or SR were included from 2010 to 2017. Overall survival (OS), progression-free survival (PFS), complication and hospital stay of those patients were compared by using propensity score matching. The registration number of this clinical trial was ChiCTR2000033983.

Results

For patients with HCC between 3 and 5 cm, the 1-, 3-, and 5- years OS rates were 90.3%, 79.7%, and 65.5% in the MWA group, and 96.7%, 88.6%, and 71%% in the SR group, respectively (p = 0.457). The 1-, 3- and 5- years PFS rates were 63.6%, 36.8% and 32.7% in the MWA group, and 74.2%, 41.9% and 35.5% in the SR group, respectively (p = 0.397). The MWA group showed fewer complications (55% versus 78.8%, p = 0.041) and shorter hospital stays (8 versus 15 days, p < 0.001) compared with the SR group.

Conclusion

MWA showed similar survival outcomes compared with SR for HCCs ranging from 3 to 5 cm. However, it showed favorable results in terms of hospital stay and complication rate compared to SR.

中文翻译：

---

与3到5厘米之间的肝细胞癌手术切除相比，微波消融显示出相似的生存结果

摘要

背景

微波消融（MWA）是一种安全有效的局部区域消融方式，但尚不清楚MWA对肝细胞癌（HCC）的疗效是否可与手术切除（SR）媲美。我们旨在比较3到5 cm的HCC患者的MWA和SR结果。

方法

从2010年至2017年，纳入了197例通过MWA或SR治疗3到5 cm HCC的患者。通过倾向评分匹配比较了这些患者的总生存期（OS），无进展生存期（PFS），并发症和住院时间。该临床试验的注册号为ChiCTR2000033983。

结果

对于3至5厘米之间的HCC患者，MWA组的1年，3年和5年OS率分别为90.3％，79.7％和65.5％，而MWA组为96.7％，88.6％和71 %% SR组（p  = 0.457）。MWA组的1年，3年和5年PFS率分别为63.6％，36.8％和32.7％，SR组分别为74.2％，41.9％和35.5％（p  = 0.397）。 与SR组相比，MWA组的并发症更少（55％对78.8％，p  = 0.041），住院时间更短（8对15天，p <0.001）。

结论

与3到5 cm的HCC相比，MWA显示出与SR相似的生存结果。但是，与SR相比，在住院时间和并发症发生率方面均显示出良好的效果。